Browse
Submit Data
Databases
API
Help

Dataset Information

7 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

A phase II trial of lenvatinib in patients with metastatic colorectal cancer after standard chemotherapy

ABSTRACT: Intervention type:DRUG Name of intervention:Lenvatinib Dose form / Japanese Medical Device Nomenclature:CAPSULE Route of administration / Site of application:ORAL Dose per administration:24mg 24mg 24mg Dosing frequency / Frequency of use:QD Planned duration of intervention:Treatment will continue until the discontinuation criteria are met. Intended dose regimen:24mg of lenvatinib is orally taken once daily for 28 days each course detailes of teratment arms:Treatment will continue with lenvatinib 24mg qd until the criteria of interruption, resuming, reduction and discontinuation of treatment are met. Dose of lenvatinib will be reduced to 20mg, 14mg, 10mg, 8mg, and 4mg qd according to the reduction criteria, and treatment will be discontinued if unable to tolerate at 4mg qd. Comparative intervention name: Dose form / Japanese Medical Device Nomenclature: Route of administration / Site of application: Dose per administration: Dosing frequency / Frequency of use: Planned duration of intervention: Intended dose regimen: Primary outcome(s): Disease control rate Study Design: Open-label, single-arm and single-center trial, no treatment control standard of care control, No, open(masking not used),

DISEASE(S): Metastatic Colorectal Cancer

PROVIDER: 98667 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Extracorporeal magnetic navigation system of capsule endoscopy

Project description:Intervention type:DEVICE Name of intervention:Comparative study between capsule endoscopy and conventional endoscopy on the accuracy and acceptability of gastrointestinal screening Dose form / Japanese Medical Device Nomenclature:DEVICE Capsule endoscopy Route of administration / Site of application:ORAL Dose per administration:1 1 1/unit Dosing frequency / Frequency of use:ONCE ONCE/Examination Planned duration of intervention:8 hours (after ingesting a capsule endoscope) Intended dose regimen:Preparation before and after(booster) ingesting a capsule endoscope, Lubiprostone intake after passing stomach detailes of teratment arms:Volunteers or digestive disease patients who underwent or will undergo upper and lower conventional endoscopy before or after a capsule endoscopy Comparative intervention name:Conventional endoscopic findings before or after capsule endoscopy Dose form / Japanese Medical Device Nomenclature:DEVICE Capsule endoscopy Route of administration / Site of application:ORAL Dose per administration:1 1 1/unit Dosing frequency / Frequency of use:ONCE ONCE Planned duration of intervention:Eight hours after ingesting a capsule endoscope Intended dose regimen:Preparation before and after(booster) ingesting a capsule endoscope Primary outcome(s): Sensitivity and specificity Study Design: Single blind no-randomized trial, uncontrolled control, No, single blind, CONFIRMATORY

| 98701 | ecrin-mdr-crc

Identification of the molecular basis of anti-cancer effect of Huaier.

Project description:Intervention type:DRUG Name of intervention:Huaier Dose form / Japanese Medical Device Nomenclature:GRANULES Route of administration / Site of application:ORAL Dose per administration:20? g Dosing frequency / Frequency of use:OTHER, SPECIFY 20g? per day Planned duration of intervention:3 months to extending if necessary Intended dose regimen:20 to 60/day by either bulk or split for 3 months to extended term if necessary detailes of teratment arms:hepatocellular carcinoma, breast cancer, colorectal cancer and related gastrointestinal cancers, urologic cancers including prostate cancer, pancreas cancer, and lung cancer, etc. Comparative intervention name:None Dose form / Japanese Medical Device Nomenclature: Route of administration / Site of application: Dose per administration: Dosing frequency / Frequency of use: Planned duration of intervention: Intended dose regimen: Primary outcome(s): For mRNA libraries, focus on mRNA studies. Data analysis includes sequencing data processing and basic sequencing data quality control, prediction of new transcripts, differential expression analysis of genes. Gene Ontology (GO) and the KEGG pathway database are used for annotation and enrichment analysis of up-regulated genes and down-regulated genes. For small RNA libraries, data analysis includes sequencing data process and sequencing data process QC, small RNA distribution across the genome, rRNA, tRNA, alignment with snRNA and snoRNA, construction of known miRNA expression pattern, prediction New miRNA and Study of their secondary structure Based on the expression pattern of miRNA, we perform not only GO / KEGG annotation and enrichment, but also different expression analysis. Study Design: Comparative test, None, No, open(masking not used), EXPLORATORY

| 98681 | ecrin-mdr-crc

A phase II trial of lenvatinib in patients with metastatic colorectal cancer after standard chemotherapy

Project description:Intervention type:DRUG. Intervention1:Lenvatinib, Dose form:CAPSULE, Route of administration:ORAL, intended dose regimen:24mg of lenvatinib is orally taken once daily for 28 days each course. Primary outcome(s): Disease control rate. Timepoint:Every 4 weeks (4th week, 8th week) until 8 weeks from the starting date of treatment , and every 8 weeks (16th week, 24th week, and so on ) after 9 weeks from the starting date of treatment.

| 2612407 | ecrin-mdr-crc

Neonatal and maternal dietary interventions in piglets

Project description:Feed additives aiming to improve gastrointestinal health are frequently supplied to piglets after weaning but might be more effective when administered before weaning. In this period, feed additives can either be administered directly to neonates, or indirectly via sow’s feed. It is yet unknown what the effect of the administration route is on gut functionality and health. Therefore, we compared the effect of different dietary interventions on gut functionality after maternal administration (lactation feed) to the neonatal administration route (oral gavage). These feed interventions included medium chain fatty acids (MCFA), beta-glucans (BG), and galacto-oligosaccharides (GOS). We measured intestinal gene expression and microbiota composition after birth (d1) and after weaning (d31). Our results show that the type of intervention and the administration route influence gut functionality (microbiome and gene expression profiles). MCFA administration led to a more differentially orchestrated response when comparing the neonatal and maternal administration route then the other two additives, indicating the route of administration of the feed interventions is determinative for the outcome. This implies that for each nutritional intervention in early life of a pig the optimal route of administration needs to be determined.

2023-06-01 | GSE229947 | GEO

A clinical trial to study the effects of two drugs, R-TPR-023 and Avastinâ?¢ in patients with Metastatic colorectal cancer

Project description:Intervention1: R-TPR-023: Dose: 5 mg/kg, Frequency: Every 2 weeks, Route of Administration: Intravenously, Duration: 3 years. Control Intervention1: Avastinâ?¢: Dose: 5 mg/kg, Frequency: Every 2 weeks, Route of Administration: Intravenously, Duration: 3 years Primary outcome(s): Outcome Name: Efficacy will be assessed as Objective Response Rate (Complete Response and Partial Response) by RECIST 1.1 criteria at 25 weeksTimepoint: 25 weeks Study Design: Randomized, Parallel Group, Active Controlled Trial Method of generating randomization sequence:Computer generated randomization Method of allocation concealment:Centralized Blinding and masking:Open Label

| 2574628 | ecrin-mdr-crc

mRNA expression data from murine hearts of control or melatonin-treated young wild type (WT) C57Bl/6 mice

Project description:Mice are 4 weeks old on a C57Bl/6N background strain, hearts were collected at ZT15, following 1 week daily administration of melatonin at 4mg/L (human equivalent of 5mg dose) in the drinking water from ZT12-15. The microarray approach allows the investigation of gene expression changes of all genes in WT control vs. WT melatonin-treated hearts.

2018-06-12 | GSE115569 | GEO

Extracorporeal magnetic navigation system of capsule endoscopy

Project description:Intervention type:DEVICE. Intervention1:Comparative study between capsule endoscopy and conventional endoscopy on the accuracy and acceptability of gastrointestinal screening, Dose form:DEVICE, Route of administration:ORAL, intended dose regimen:Preparation before and after(booster) ingesting a capsule endoscope, Lubiprostone intake after passing stomach. Control intervention1:Conventional endoscopic findings before or after capsule endoscopy, Dose form:DEVICE, Route of administration:ORAL, Intended dose regimen:Preparation before and after(booster) ingesting a capsule endoscope. Primary outcome(s): Sensitivity and specificity. Timepoint:After acquiring data from 40 subjects.

| 2612263 | ecrin-mdr-crc

Danlu Tongdu Tablets: Safety evaluation and mechanism of hepatotoxicity in Sprague-Dawley rats

Project description:Based on the acute and chronic toxicity study, we further focused on the impact of Danlu Tongdu (DLTD) on the liver. At the end of 26 weeks of administration, 4 male rats were selected from the control group and the high-dose group respectively for transcriptome analysis. The selection criteria were random selection from the control group, the four rats selected from the high-dose. group showed pathological changes in the liver.

2022-08-25 | GSE212036 | GEO

Her1 vaccine in metastatic colon and prostate cancer

Project description:Interventions: All patients included in the study will be treated with the HER1 vaccine. Dose: Initially 2 dose levels (400µg and 800µg) will be opened in each stratum (prostate and colon). In the event of closure of both dose levels due to some stop criteria, another dose (1200 µg) will be opened. Route of administration: Intramuscular. Treatment frequency: Every 14 days during the first five administrations (approximately 2 months) and subsequently, every 28 days for the remaining ten immunizations, until discontinuation for any of the reasons provided for in the research protocol or upon completion of 12 months of treatment. . The treatment period will be 336 days, approximately 12 months.;ErbB Receptors;Vaccines;Injections, Intramuscular;HER1, therapeutic vaccine Primary outcome(s): Proportion of patients with serious adverse events with a causal relationship (according to CTCAE criteria and causality criteria: SAE with very probable, probable or possible causation). Measurement time: at all times of administration of the research product. Study Design: Allocation: N/A: single arm study. Masking: Open. Control group: Uncontrolled. Assignment: Single group. Purpose: Treatment

| 94899 | ecrin-mdr-crc

Effects of dexamethasone on human skeletal muscle and adipose tissue

Project description:Context: Glucocorticoids are frequently prescribed drugs with important side-effects such as glucose intolerance and tissue remodelling. Objective: The goal was to explore the molecular basis of the crosstalk between adipose tissue and skeletal muscle during short term glucocorticoid treatment. Design and Intervention: Healthy male subjects were assigned to a 4-d treatment with dexamethasone at 4mg/d. Main Outcome Measures: Primary outcome measures were gene expression profiling of adipose tissue and skeletal muscle. Urinary cortisol and metabolic biochemistry were also assessed. Dexamethasone was provided in 0.5 mg tablets as 4mg per day during 4 days to male healthy volunteers. Skeletal muscle and adipose tissue biopsies were obtained at the beginning and at the end of the protocol. The transcriptome analysis compared before vs. after the 4 days dexamethasone treatment using a dye swap design and whole genome 4x44k oligonucleotide arrays (Agilent Technologies).

2011-11-28 | E-GEOD-17992 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data